Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Sees A Venture Capital Trend: Identify And Bring In The Buyer Early

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.

You may also be interested in...



Covidien Pure-Play: Pharma Spinoff In The Works

Covidien says it has been working for several years toward separating out its pharma business from its larger and more profitable devices/supplies division.

Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects

Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.

Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly

Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel